ACTION OF 1α-HYDROXY VITAMIN D3 ON CALCIUM ABSORPTION AND BONE RESORPTION IN MAN

Munro Peacock, J. C. Gallagher, B. E C Nordin

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Synthetic 1α-hydroxy-vitamin D3 (1α-hydroxycholecalciferol, 1α-H.C.C.) was given orally in a dose of 25 μg. per day to groups of patients in whom calcium malabsorption is a recognised feature. Patients responded with an increase in plasma calcium and phosphate and in calcium absorption irrespective of their pre-treatment values. Net calcium resorption from bone was increased in all patients with normal renal function. In patients with renal failure, however, net bone resorption tended to decrease. The onset of action was rapid and could be seen within 24 hours. On stopping the vitamin the effects were not maintained and their disappearance depended on the duration of treatment. 1α-H.C.C. is very potent in man and will be useful in treatment of patients with calcium malabsorption. The malabsorption of calcium of elderly people is not due to failure of the absorptive mechanism in the small bowel since it responds to 1α-H.C.C. but the dose will need to be less than 25 μg. per day to avoid excessive bone resorption and hypercalcaemia.

Original languageEnglish (US)
Pages (from-to)385-389
Number of pages5
JournalThe Lancet
Volume303
Issue number7854
DOIs
StatePublished - Mar 9 1974
Externally publishedYes

Fingerprint

Cholecalciferol
Bone Resorption
Calcium
Hypercalcemia
Vitamins
Renal Insufficiency
Therapeutics
Kidney
alfacalcidol

ASJC Scopus subject areas

  • Medicine(all)

Cite this

ACTION OF 1α-HYDROXY VITAMIN D3 ON CALCIUM ABSORPTION AND BONE RESORPTION IN MAN. / Peacock, Munro; Gallagher, J. C.; Nordin, B. E C.

In: The Lancet, Vol. 303, No. 7854, 09.03.1974, p. 385-389.

Research output: Contribution to journalArticle

Peacock, Munro ; Gallagher, J. C. ; Nordin, B. E C. / ACTION OF 1α-HYDROXY VITAMIN D3 ON CALCIUM ABSORPTION AND BONE RESORPTION IN MAN. In: The Lancet. 1974 ; Vol. 303, No. 7854. pp. 385-389.
@article{11e5edd2c38e4fa983cf6f27c8394b1c,
title = "ACTION OF 1α-HYDROXY VITAMIN D3 ON CALCIUM ABSORPTION AND BONE RESORPTION IN MAN",
abstract = "Synthetic 1α-hydroxy-vitamin D3 (1α-hydroxycholecalciferol, 1α-H.C.C.) was given orally in a dose of 25 μg. per day to groups of patients in whom calcium malabsorption is a recognised feature. Patients responded with an increase in plasma calcium and phosphate and in calcium absorption irrespective of their pre-treatment values. Net calcium resorption from bone was increased in all patients with normal renal function. In patients with renal failure, however, net bone resorption tended to decrease. The onset of action was rapid and could be seen within 24 hours. On stopping the vitamin the effects were not maintained and their disappearance depended on the duration of treatment. 1α-H.C.C. is very potent in man and will be useful in treatment of patients with calcium malabsorption. The malabsorption of calcium of elderly people is not due to failure of the absorptive mechanism in the small bowel since it responds to 1α-H.C.C. but the dose will need to be less than 25 μg. per day to avoid excessive bone resorption and hypercalcaemia.",
author = "Munro Peacock and Gallagher, {J. C.} and Nordin, {B. E C}",
year = "1974",
month = "3",
day = "9",
doi = "10.1016/S0140-6736(74)93150-X",
language = "English (US)",
volume = "303",
pages = "385--389",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "7854",

}

TY - JOUR

T1 - ACTION OF 1α-HYDROXY VITAMIN D3 ON CALCIUM ABSORPTION AND BONE RESORPTION IN MAN

AU - Peacock, Munro

AU - Gallagher, J. C.

AU - Nordin, B. E C

PY - 1974/3/9

Y1 - 1974/3/9

N2 - Synthetic 1α-hydroxy-vitamin D3 (1α-hydroxycholecalciferol, 1α-H.C.C.) was given orally in a dose of 25 μg. per day to groups of patients in whom calcium malabsorption is a recognised feature. Patients responded with an increase in plasma calcium and phosphate and in calcium absorption irrespective of their pre-treatment values. Net calcium resorption from bone was increased in all patients with normal renal function. In patients with renal failure, however, net bone resorption tended to decrease. The onset of action was rapid and could be seen within 24 hours. On stopping the vitamin the effects were not maintained and their disappearance depended on the duration of treatment. 1α-H.C.C. is very potent in man and will be useful in treatment of patients with calcium malabsorption. The malabsorption of calcium of elderly people is not due to failure of the absorptive mechanism in the small bowel since it responds to 1α-H.C.C. but the dose will need to be less than 25 μg. per day to avoid excessive bone resorption and hypercalcaemia.

AB - Synthetic 1α-hydroxy-vitamin D3 (1α-hydroxycholecalciferol, 1α-H.C.C.) was given orally in a dose of 25 μg. per day to groups of patients in whom calcium malabsorption is a recognised feature. Patients responded with an increase in plasma calcium and phosphate and in calcium absorption irrespective of their pre-treatment values. Net calcium resorption from bone was increased in all patients with normal renal function. In patients with renal failure, however, net bone resorption tended to decrease. The onset of action was rapid and could be seen within 24 hours. On stopping the vitamin the effects were not maintained and their disappearance depended on the duration of treatment. 1α-H.C.C. is very potent in man and will be useful in treatment of patients with calcium malabsorption. The malabsorption of calcium of elderly people is not due to failure of the absorptive mechanism in the small bowel since it responds to 1α-H.C.C. but the dose will need to be less than 25 μg. per day to avoid excessive bone resorption and hypercalcaemia.

UR - http://www.scopus.com/inward/record.url?scp=0015945299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015945299&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(74)93150-X

DO - 10.1016/S0140-6736(74)93150-X

M3 - Article

VL - 303

SP - 385

EP - 389

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 7854

ER -